Antineoplastic Agents, Hormonal

"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Descriptor ID	D018931
MeSH Number(s)	D27.505.954.248.169
Concept/Terms	Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Hormonal Agents, Antineoplastic Hormonal Antineoplastic Agents Hormonal Antineoplastics Antineoplastic Hormonal Drugs Drugs, Antineoplastic Hormonal Hormonal Drugs, Antineoplastic Hormonal Antineoplastic Drugs Antineoplastics, Hormonal Antineoplastic Hormonal Agents Agents, Antineoplastic Hormonal Antineoplastic Drugs, Hormonal

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Hormonal [D27.505.954.248.169]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Hormonal".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.

Bar chart showing 32 publications over 18 distinct years, with a maximum of 4 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	3	1	4
2006	1	0	1
2008	1	1	2
2009	0	1	1
2010	2	0	2
2011	1	1	2
2012	1	0	1
2013	1	0	1
2014	1	0	1
2015	1	2	3
2016	1	0	1
2017	1	2	3
2018	2	0	2
2019	1	1	2
2020	2	0	2
2021	1	0	1
2024	1	0	1
2025	2	0	2

Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.

Gonzales Iv M, Garcia-Alcaraz C, Kaur N, Baglione AN, Livermon S, Barnes LE, Wells KJ. Improving Long-Term Adherence to Endocrine Therapy Among Breast Cancer Survivors: Development of a Multiscale Modeling and Intervention System. JMIR Cancer. 2026 Apr 30; 12:e68255.

View in: PubMed
Johnson Powell C, Adigwe A, Ekezie N, Fatima B, Majd Z, Collins R, Houk K, Patel T, Ma H, Shimko R, Ononogbu O, Abughosh S, Trivedi MV. Interventions to improve adherence to oral endocrine therapy for prevention or treatment of breast cancer in Black women of low socioeconomic status. Support Care Cancer. 2025 Dec 11; 34(1):24.

View in: PubMed
Lee HH, Siu-Li N, Pagano I, Fukui JA. Examining a Genomic Test in Predicting Extended Endocrine Benefit and Recurrence Risk in a Diverse Breast Cancer Population. Curr Oncol. 2025 Sep 25; 32(10).

View in: PubMed
Lazarte JMS, Ofosu-Asante K, Tilghman SL, Lamango NS. PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion. Oncotarget. 2025 Jul 29; 16:621-641.

View in: PubMed
Jones V, Yin HH, Yuan YC, Wang Y, Li SM, Aljaber D, Sanchez A, Quinones C, Schmolze D, Yuan Y, Mortimer J, Yee L, Kruper L, Jovanovic-Talisman T, Tomsic J, Sanchez N, Chavez T, O'Regan RM, Khan QJ, Davis M, Kalinsky K, Meisel J, Kittles R, Rodriguez-Rodriguez L, Seewaldt V. Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer. Sci Rep. 2025 Feb 28; 15(1):7220.

View in: PubMed
Chang CY, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, Lo-Ciganic WH. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors. Br J Cancer. 2024 Jun; 130(12):1943-1950.

View in: PubMed
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open. 2021 10 01; 4(10):e2130587.

View in: PubMed
Mavingire N, Campbell P, Wooten J, Aja J, Davis MB, Loaiza-Perez A, Brantley E. Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes. Cancer Lett. 2021 03 01; 500:64-74.

View in: PubMed
Bahnassy S, Thangavel H, Quttina M, Khan AF, Dhanyalayam D, Ritho J, Karami S, Ren J, Bawa-Khalfe T. Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer. Cell Commun Signal. 2020 09 18; 18(1):154.

View in: PubMed
Shah CH, Balkrishnan R, Diaby V, Xiao H. Examining factors associated with adherence to hormonal therapy in breast cancer patients. Res Social Adm Pharm. 2020 04; 16(4):574-582.

View in: PubMed

People

Explore

Similar Concepts

Top Journals